FEEDBACK PLC — Regulatory Filings 2019

Jul 26, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8929G

Feedback PLC

26 July 2019

Feedback plc

BleepaTM - revolutionising clinical messaging

New medical grade imaging app to be launched at NHS Expo on 4-5 September 2019

Cambridge, 26 July 2019: Further to the Company's strategic review announcement on 10 July 2019, Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today provides an update on its new clinical messaging product: BleepaTM.

As previously announced, Feedback plans to establish a leading role in the medical communication market. BleepaTM, its new app for clinicians, is currently in beta development and will be formally launched at NHS Expo on 4-5 September 2019 in Manchester.

Based on Feedback's Cadran technology, BleepaTM is a secure, encrypted medical communication tool accessible through smartphones, tablets and desktops that facilitates rapid clinical messaging and review of medical grade imaging for all members of a clinical team, directly from a hospital Picture Archiving and Communications System (PACS). BleepaTM enables faster clinical decision making between team members wherever they are, accelerating and improving patient care.

According to an article published in BMJ Innovations, 97% of hospital doctors routinely use WhatsApp to communicate about patients.1

This increasing trend for clinicians to use personal devices to discuss patient care and make clinical decisions is more convenient and efficient than traditional methods of clinical communication. However, using such methods opens doctors and their patients up to a variety of risks.

BleepaTM addresses growing concerns about these messaging platforms not meeting diagnostics clinical standards and regarding patient data protection. Continued use of non-specialist communication tools could leave both hospitals and individual clinical users significantly exposed and therefore open to the risk of litigation.

The Directors believe BleepaTM will be the only communication tool to be a CE marked medical device. More information can be found at www.bleepa.com.

Dr Tom Oakley, CEO of Feedback, commented:

"We are making rapid progress in the development of our new messaging app, BleepaTM. We believe that it will provide a flexible, accurate and secure method for swift clinical decision making, revolutionising the way in which patients receive treatment whilst safeguarding our doctors from potential litigation. We look forward to showcasing the finished product this September at NHS Expo in Manchester."

1 O'Sullivan DM, O'Sullivan E, O'Connor M, et al WhatsApp Doc? BMJ Innovations 2017;3:238-239.

-Ends-

Enquiries:

Feedback plc	+44 (0)1954 718072
Tom Oakley, CEO	IR@fbk.com
Lindsay Melvin, CFO
Instinctif Partners	+44 207 457 2020
Rozi Morris/Phillip Marriage	Feedbackplc@instinctif.com

Notes to editors About Feedback plc

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer. Feedback Medical works with customers globally from headquarters in the internationally renowned scientific hub of Cambridge, UK. Its proprietary technologies are TexRAD®, the quantitative texture analysis tool and Cadran, a picture archiving communication system (PACS). For more information, see www.fbk.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAFQLFLKDFBBBF